Lung NeoplasmsAVP-LungNCT07573748
Apple Vision Pro-Assisted Vascular Identification in Lung Surgery
A study testing Apple Vision Pro in people with Lung Neoplasms and Mixed Reality, run by The Second People's Hospital of Huai'an.
Trial summary
This study is testing whether a new mixed-reality head-mounted display (Apple Vision Pro) can help surgeons see blood vessels more clearly during lung surgery. During the operation, doctors usually need to identify and protect important blood vessels to avoid bleeding. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Lung Neoplasms, Mixed Reality
- What is being tested?
- Apple Vision Pro
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- No sites listed yet
- Study dates
- 1 May 2026to 1 Jul 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients aged 18 years or older. Diagnosed with lung nodules or early-stage lung cancer requiring surgical resection (lobectomy or segmentectomy).
- Scheduled for elective lung surgery at Huai'an Second People's Hospital. American Society of Anesthesiologists (ASA) Physical Status Classification I-III.
- Ability to understand and sign the informed consent form. Willingness to undergo surgery with the Apple Vision Pro navigation assistance.
Who cannot join
- Patients under 18 years of age. Pregnant or breastfeeding women. Patients with severe cardiopulmonary dysfunction (e.g., severe COPD, unstable angina, recent myocardial infarction) that would contraindicate surgery.
- Participation in another interventional clinical trial within the past 30 days. Inability to cooperate with the surgical team or follow study procedures.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Apple Vision Pro-Assisted Vascular Identification in Lung Surgery: A Prospective Interventional Study
This study is testing whether a new mixed-reality head-mounted display (Apple Vision Pro) can help surgeons see blood vessels more clearly during lung surgery.
During the operation, doctors usually need to identify and protect important blood vessels to avoid bleeding. In this study, surgeons will wear the Apple Vision Pro device, which shows 3D images of the lungs and blood vessels. This may help them find vessels more accurately and make surgery safer.
Read more
Participants scheduled for lung surgery at Huai'an Second People's Hospital will be invited to join. Before the operation, participants will have a CT scan. During surgery, doctors will use the device while performing the procedure.
The study does not change the standard surgical steps, and there are no extra risks for participants. The main goal is to see if this new technology makes surgery easier and safer.
Participation is voluntary, and all personal information will be kept confidential.
Read the detailed description
Background:
Precise identification of pulmonary blood vessels is critical in thoracic surgery to prevent intraoperative bleeding and complications. Conventional methods rely on direct visual inspection and preoperative imaging review. Recent advances in extended reality (XR) technology offer potential for real-time, three-dimensional visualization during surgery.
Objective:
This study aims to evaluate the feasibility and safety of using Apple Vision Pro, a mixed-reality head-mounted display, to assist surgeons in identifying and navigating blood vessels during lung surgery.
Methods:
This is a single-center, prospective clinical study conducted at Huai'an Second People's Hospital. Patients undergoing elective lung surgery will be enrolled. All participants will receive standard preoperative chest CT scans.
During surgery, the surgical team will use Apple Vision Pro to visualize reconstructed 3D vascular models superimposed on the surgical field. The primary outcome is the accuracy of vessel identification and navigation. Secondary outcomes include operative time, blood loss, complication rates, and surgeon feedback on usability.
Ethical Considerations:
The study protocol has been approved by the Medical Ethics Committee of Huai'an Second People's Hospital. Informed consent will be obtained from all participants prior to enrollment.
Significance:
If successful, this study may provide a novel technological approach to improving surgical precision and safety in thoracic surgery.
- Conditions
- Lung Neoplasms, Mixed Reality
- Being tested
- Apple Vision Pro
- Keywords
- Lung Neoplasms, Mixed reality, Intraoperative Navigation, Three-Dimensional Imaging
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Apple Vision ProDevice
Use of Apple Vision Pro headset for augmented reality-assisted surgical navigation during lung surgery. The device will be worn by the surgeon to visualize critical anatomical structures and navigation pathways in real-time.
| Study group | Role | What they receive |
|---|---|---|
| Experimental | Experimental | Participants in this arm will undergo lung surgery using Apple Vision Pro for intraoperative vascular navigation Receives: Device: Apple Vision Pro |
What is being measured
The primary outcome is the main question the study is designed to answer.
Accuracy of Perivascular Anatomical Identification
The primary outcome is the accuracy of identifying critical perivascular anatomical structures (including pulmonary arteries, veins, and bronchi) using Apple Vision Pro. Accuracy will be measured by comparing the real-time navigation display with the actual anatomy confirmed by the surgeon during dissection. The primary endpoint is the successful identification of the correct transection plane that avoids injury to adjacent arteries, veins, or bronchi. Any discrepancy leading to potential mis-transection will be recorded.
Measured: During the critical dissection and transection phase of lung surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 May 2026
- Study start1 May 2026 (estimated)
- Primary completion1 Jun 2026 (estimated)
- Study completion1 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Lung NeoplasmsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- This is a single-arm, prospective study. All participants will undergo standard-of-care lung surgery with the addition of the Apple Vision Pro mixed-reality headset for intraoperative vascular navigation. There is no control group.
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The Second People's Hospital of Huai'an
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Xiaohua Zuo, The Second People's Hospital of Huai'an
- Investigators
- Chuxu Wang, Attending Physician, Principal investigator, The Second People's Hospital of Huai'an
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07573748
- Sponsor's protocol ID
- HEYLL202654
- Acronym
- AVP-Lung
- Status last verified
- Apr 2026
- First submitted
- 24 Apr 2026
- Last updated
- 7 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: This is a single-center study with a limited sample size and specific local protocol. Due to resource constraints and the focus on immediate clinical outcomes for this specific cohort, data sharing is not planned at this time.
Publications
Zhou AE, Klufas T, Feng H. Leveraging Apple Vision Pro for Dermatologic Surgery Education and Intraoperative Recording. Indian Dermatol Online J. 2026 Mar 1;17(2):294-295. doi: 10.4103/idoj.idoj_692_25. Epub 2025 Dec 12. No abstract available.
PubMed 41403068Shen K, Li W, Xie Z. Preliminary application of Apple Vision Pro (AVP) in laparoscopic gastrointestinal surgery. Int J Surg. 2025 Nov 1;111(11):7898-7905. doi: 10.1097/JS9.0000000000003066. Epub 2025 Jul 17.
PubMed 40679982Li C. Apple Vision Pro as an augmentative tool in surgery: a double-edged scalpel. Ann Med Surg (Lond). 2024 Oct 11;86(11):6407-6408. doi: 10.1097/MS9.0000000000002645. eCollection 2024 Nov. No abstract available.
PubMed 39525735Shanbhag NM, Bin Sumaida A, Al Shamisi K, Balaraj K. Apple Vision Pro: A Paradigm Shift in Medical Technology. Cureus. 2024 Sep 17;16(9):e69608. doi: 10.7759/cureus.69608. eCollection 2024 Sep.
PubMed 39308843
Study at a glance
From the registry record, last updated by the sponsor on 7 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Apple Vision Pro-Assisted Vascular Identification in Lung Surgery: A Prospective Interventional Study
- ClinicalTrials.gov ID
- NCT07573748
- Acronym / sponsor ID
- AVP-Lung / HEYLL202654
- Conditions
- Lung Neoplasms, Mixed Reality
- Keywords
- Lung Neoplasms, Mixed reality, Intraoperative Navigation, Three-Dimensional Imaging
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- The Second People's Hospital of Huai'anUniversity, hospital or other
- Study start
- 1 May 2026 (estimated)
- Primary completion
- 1 Jun 2026 (estimated)
- Study completion
- 1 Jul 2026 (estimated)
- First posted
- 7 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is testing whether a new mixed-reality head-mounted display (Apple Vision Pro) can help surgeons see blood vessels more clearly during lung surgery.
During the operation, doctors usually need to identify and protect important blood vessels to avoid bleeding. In this study, surgeons will wear the Apple Vision Pro device, which shows 3D images of the lungs and blood vessels. This may help them find vessels more accurately and make surgery safer.
Participants scheduled for lung surgery at Huai'an Second People's Hospital will be invited to join. Before the operation, participants will have a CT scan. During surgery, doctors will use the device while performing the procedure.
The study does not change the standard surgical steps, and there are no extra risks for participants. The main goal is to see if this new technology makes surgery easier and safer.
Participation is voluntary, and all personal information will be kept confidential.
Detailed description
Background:
Precise identification of pulmonary blood vessels is critical in thoracic surgery to prevent intraoperative bleeding and complications. Conventional methods rely on direct visual inspection and preoperative imaging review. Recent advances in extended reality (XR) technology offer potential for real-time, three-dimensional visualization during surgery.
Objective:
This study aims to evaluate the feasibility and safety of using Apple Vision Pro, a mixed-reality head-mounted display, to assist surgeons in identifying and navigating blood vessels during lung surgery.
Methods:
This is a single-center, prospective clinical study conducted at Huai'an Second People's Hospital. Patients undergoing elective lung surgery will be enrolled. All participants will receive standard preoperative chest CT scans.
During surgery, the surgical team will use Apple Vision Pro to visualize reconstructed 3D vascular models superimposed on the surgical field. The primary outcome is the accuracy of vessel identification and navigation. Secondary outcomes include operative time, blood loss, complication rates, and surgeon feedback on usability.
Ethical Considerations:
The study protocol has been approved by the Medical Ethics Committee of Huai'an Second People's Hospital. Informed consent will be obtained from all participants prior to enrollment.
Significance:
If successful, this study may provide a novel technological approach to improving surgical precision and safety in thoracic surgery.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- This is a single-arm, prospective study. All participants will undergo standard-of-care lung surgery with the addition of the Apple Vision Pro mixed-reality headset for intraoperative vascular navigation. There is no control group.
| Arm | Type | Receives |
|---|---|---|
| Experimental | Experimental | Device: Apple Vision ProParticipants in this arm will undergo lung surgery using Apple Vision Pro for intraoperative vascular navigation |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Patients aged 18 years or older. Diagnosed with lung nodules or early-stage lung cancer requiring surgical resection (lobectomy or segmentectomy).
- Scheduled for elective lung surgery at Huai'an Second People's Hospital. American Society of Anesthesiologists (ASA) Physical Status Classification I-III.
- Ability to understand and sign the informed consent form. Willingness to undergo surgery with the Apple Vision Pro navigation assistance.
Key exclusion criteria (2 listed)
- Patients under 18 years of age. Pregnant or breastfeeding women. Patients with severe cardiopulmonary dysfunction (e.g., severe COPD, unstable angina, recent myocardial infarction) that would contraindicate surgery.
- Participation in another interventional clinical trial within the past 30 days. Inability to cooperate with the surgical team or follow study procedures.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Apple Vision ProUse of Apple Vision Pro headset for augmented reality-assisted surgical navigation during lung surgery. The device will be worn by the surgeon to visualize critical anatomical structures and navigation pathways in real-time. | Device | Experimental |
Primary outcome
Accuracy of Perivascular Anatomical Identification
Time frame: During the critical dissection and transection phase of lung surgery
The primary outcome is the accuracy of identifying critical perivascular anatomical structures (including pulmonary arteries, veins, and bronchi) using Apple Vision Pro. Accuracy will be measured by comparing the real-time navigation display with the actual anatomy confirmed by the surgeon during dissection. The primary endpoint is the successful identification of the correct transection plane that avoids injury to adjacent arteries, veins, or bronchi. Any discrepancy leading to potential mis-transection will be recorded.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 May 2026.
- Background: PubMed 41403068Zhou AE, Klufas T, Feng H. Leveraging Apple Vision Pro for Dermatologic Surgery Education and Intraoperative Recording. Indian Dermatol Online J. 2026 Mar 1;17(2):294-295. doi: 10.4103/idoj.idoj_692_25. Epub 2025 Dec 12. No abstract available.
- Background: PubMed 40679982Shen K, Li W, Xie Z. Preliminary application of Apple Vision Pro (AVP) in laparoscopic gastrointestinal surgery. Int J Surg. 2025 Nov 1;111(11):7898-7905. doi: 10.1097/JS9.0000000000003066. Epub 2025 Jul 17.
- Background: PubMed 39525735Li C. Apple Vision Pro as an augmentative tool in surgery: a double-edged scalpel. Ann Med Surg (Lond). 2024 Oct 11;86(11):6407-6408. doi: 10.1097/MS9.0000000000002645. eCollection 2024 Nov. No abstract available.
- Background: PubMed 39308843Shanbhag NM, Bin Sumaida A, Al Shamisi K, Balaraj K. Apple Vision Pro: A Paradigm Shift in Medical Technology. Cureus. 2024 Sep 17;16(9):e69608. doi: 10.7759/cureus.69608. eCollection 2024 Sep.
- Individual participant dataSharing planned: No. This is a single-center study with a limited sample size and specific local protocol. Due to resource constraints and the focus on immediate clinical outcomes for this specific cohort, data sharing is not planned at this time.
Related trials for Lung Neoplasms
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
RecruitingPhase 2/3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
RecruitingPhase 3
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Non-small Cell Lung Cancer
Recruiting
More Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes After Childhood ALL and Other Cancers - a Monocentric Late Effects Study (MaximALL)
Acute Lymphatic Leukemia, Lymphoma
RecruitingPhase 1
SW-682 in Advanced Solid Tumors
Advanced Solid Tumor, Mesothelioma, Malignant
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Chuxu Wang, Attending Physician principal investigator
The Second People's Hospital of Huai'an
Questions about this trial
What is this clinical trial studying?
A study testing Apple Vision Pro in people with Lung Neoplasms and Mixed Reality, run by The Second People's Hospital of Huai'an.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 7 May 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Chuxu Wang, Attending Physician (+86 15996195616, wangchuxu@qq.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Accuracy of Perivascular Anatomical Identification (time frame: During the critical dissection and transection phase of lung surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07573748, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 May 2026.